Therapeutic activity of NK cells against tumors

International Reviews of Immunology

Volumn 20, Issue 3-4, 2001, Pages 439-502

  Basse, P H ^a   Whiteside, T L ^a   Chambers, W ^a   Herberman, R B ^a  

^a NONE

Author keywords

Adoptive transfer; Biological response modifiers; Glioma; Interleukin 2; Melanoma; Natural killer cells

Indexed keywords

EID: 0035212506     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830180109054416     Document Type: Review

References (249)

1. Impaired NK cell profile in leukemia patients
2. Characterization of natural killer cells and lymphokine activated killer cells
3. NK cell and NAB antitumor activity in vivo
4. The role of granulocytes in host defense against tumors
5. Effect of carbohydrates on the in vivo migration of purified LAK cells
6. Immunologically privileged sites
7. Functional capacity of solid tissue transplants in the brain: Evidence for immunologic privilege
8. Immunity to homologous grafted skin. II. The fate of skin homografts to the brain, to subcutaneous tissue, and to the anterior chamber of the eye
9. The detailed distribution of HLA-A,B,C antigens in normal human organs
10. The detailed distribution of MHC Class II antigens in normal human organs
11. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means
12. Activated T lymphocytes produce a matrix-degrading heparin sulfate endoglycosidase
13. Cellular immune reactivity within the CNS
14. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view
15. Graft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system
16. MHC expression in spontaneous and induced rejection of neural xenografts
17. Immunological reactions induced by intracerebral transplantation: Evidence that host microglia but not astroglia are the antigen presenting cells
18. Brain macrophages: Evaluation of microglia and their functions
19. Immunobiology of brain tumors and implications of immunotherapy
20. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ
21. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions
22. Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity
23. Analysis of B7-1 and B7-2 costimulatory ligands in cultured mouse microglia: Upregulation by interferon-gamma and lipopolysaccharide and downregulation by interleukin-10, prostaglandin E2 and cyclic AMP-elevating agents
24. Presentation of proteolipid protein epitopes and B7-I-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes
25. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells
26. Inducible expression of H-2 and Ia antigens on brain cells
27. Astrocytes present myelin basic protein to encephalitogenic T-cell lines
28. Pathology of human intracranial neoplasia
29. Lymphocytic infiltration of intracranial tumors. Morphologic evidence for a host-immune reaction and comparison with the leukocyte migration test
30. Mononuclear infiltrates in human brain tumors: Possible morphological equivilence of an immunological defense reaction
31. Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment. I. Glioblastoma
32. Glioblastoma multiforme
33. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors
34. Risk and prognostic factors in trophoblastic neoplasia
35. Host resistance and survival in carcinoma of the breast: A study of 104 cases of medullary carcioma in a series of 1,411 cases of breast cancer followed for 20 years
36. What's new in natural killer cells?
37. Lymphoreticular infiltration in human tumors: Prognostic and biological implications
38. Characterization of host mononuclear cells in gliomas (Abstr.)
39. Presence of lymphocyte surface markers on "small cells" in pineal germinoma
40. Immunofluorescence study of lymphocytic infiltration in gliomas
41. Immunohistologic evaluation of the lymphoreticular infiltrate in human central nervous system tumors
42. The immunopathology of brain tumours
43. Expression of human markers shared between human natural killer cells and neuroblastoma lines
44. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule
45. Characterization of the lymphoid cells isolated from human gliomas
46. Presence and significance of NK cells in glioblastomas
47. NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function
48. Modulation of T-cell function by gliomas
49. Immunoregulatory cell-function in peripheral blood leukocytes of patients with intracranial gliomas
50. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies
51. Regulation of natural killer cell function by glass-adherent cells in patients with intracranial malignancies
52. Suppression of splenic natural killer cell activity in rats with brain tumors
53. Inhibition of cell-mediated immunity in patients with brain tumors
54. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers
55. Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor
56. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
57. Malignant glioma modulation of immune function: Relative contribution of different soluble factors
58. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells
59. 2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes
60. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
61. T-cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β
62. Differential expression of transforming growth factor-β1, β2, and β3 by glioblastoma cells, astrocytes, and microglia
63. Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line
64. Transforming growth factor beta 1 (TGF-β1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant
65. Tumor-derived transforming growth factor-beta 1 and interleukin-6 are chemotactic for lymphokine-activated killer cells
66. Transforming growth factor-beta 1 is chemotactic for interleukin-2-activated natural killer cells
67. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1
68. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T-cells
69. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2
70. Transforming growth factor-β2 down-regulates HLA-DR antigen expression on human malignant glioma cells
71. Inhibition of interferon-α-induced major histocompatibility complex class II gene transcription by interferon-β and type β1 transforming growth factor in human astrocytoma cells
72. Transforming growth factor-β suppresses activation and proliferation of microglia in vitro
73. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas
74. Autologous serological responses in glioma patients-correlation with tumor grade and survival
75. Advances in the biological therapy and gene therapy of malignant disease
76. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors
77. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): Antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer
78. Mechanisms of interferon action
79. Human brain tumor-derived cell lines: Growth rate reduced by human fibroblast interferon
80. Growth inhibitory effect of recombinant α and β interferon on human glioma cells
81. Immunobiology of brain tumors
82. High dose interferon alpha therapy in the treatment of progressive primary malignant brain tumors
83. Clinical effect of interferon in malignant brain tumors
84. Clinical trials of interferon-β (MR-21) On malignant brain tumors
85. Systemic beta-interferon therapy for recurrent gliomas: A brief report
86. Modulation of human leukocyte antigen DR expression in glioblastoma cells by interferon gamma and other cytokines
87. Effects of α-interferon on major histocompatibility complex antigen expression and lymphocyte infiltration in the 9L gliosarcoma brain tumor model: Implications for strategies of immunotherapy
88. Rat ependyma and microglial cells express class II MHC antigens after intravenous infusion of recombinant gamma interferon
89. Systemic gamma-interferon therapy for recurrent gliomas
90. Randomised, controlled study of intratumoral recombinant α-interferon treatment in newly diagnosed glioblastoma
91. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas
92. Effects of human recombinant interferon-gamma on immunological parameters in brain tumor patients - Peport of two cases
93. Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme
94. Immunotherapy with autologous white cell infusions ("lymphocytes") in the treatment of recurrent glioblastoma multiforme. A preliminary report
95. Sterile sorting of Leu-11a-positive cells (NK cells) using flow cytometry and the antineoplastic effects on brain tumors
96. Antineoplastic effects of natural killer cells sorted with flow cytometry on brain tumors
97. Intratumoral injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of gliomblastoma
98. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial
99. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with malignant brain tumors
100. Intratumoral LAK cell and interleukin-2 therapy of human gliomas
101. Intratumoral infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2) for the treatment of patients with malignant brain tumor
102. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
103. Natural killer cells and tumor therapy
104. The role of natural killer cells in human disease
105. Familial occurrence of breast cancer is associated with reduced natural killer activity
106. Role of natural killer cells in immune surveillance of cancer
107. Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential
108. Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease
109. Nonsecretory apoptotic killing by human NK cells
110. Constitutive expression and role of the tumor necrosis factor family ligands in apoptotic killing of tumor cells by human natural killer cells
111. Express yourself or die: Peptides, Mhc molecules and NK cells
112. Natural killer receptors
113. Regulation through inhibitory receptors
114. Characteristics of natural killer cells and lymphokine-activated killer cells. Their role in the biology and treatment of human cancer
115. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes form the liver
116. Accumulation of natural killer and cytotoxic T large granular lymphocytes in the liver during virus infection
117. Changes of liver-resident natural killer cells during liver regeneration in rats
118. 1 integrins
119. Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production and cell proliferation
120. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
121. Perspectives on the use of interleukin-2 in cancer treatment
122. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
123. Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma
124. Interleukin-2 in metastatic melanoma: Establishing a role
125. Renal cell carcinoma and interleukin-2: What are the end-points?
126. Functional consequences of IL-2 receptor expression on resting human lymphocytes: Identification of a novel NK cell subset
127. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2
128. Clincial and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation
129. Cytokine and cellular mediated immunotherapy
130. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic
131. Enhance antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic
132. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2
133. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL2
134. Antitumor activities of subsets of human IL2-activated natural killer cells in solid tissues
135. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2
136. Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous cell carcinoma of the head and neck established in nude mice
137. Human tumor antigen-specific T lymphocytes and IL2-activated natural killer (A-NK) cells: Comparisons of antitumor effects in vitro and in vivo
138. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells
139. Elimination of established liver metastases by human IL-2 activated natural killer cells after locoregional or systemic adoptive transfer
140. Human gastric carcinoma transduced with the IL-2 gene: Increased sensitivity to immune effector cells in vitro and in vivo
141. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells
142. Stable transduction of the IL-2 gene into human natural killer cell lines and their phenotypic & functional characterization in vitro and in vivo
143. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy
144. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92
145. In vitro generation and in vivo effects of adherent lymphokine-activated killer (ALAK) cells and IL2 in patients with solid tumors
146. Characterization of human NK cells obtained from cancer patients and cultured for adoptive immunotherapy. AAI/CIS Proc., Denver, CO. May 21-25
147. Post-transplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer
148. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with A-NK cells in the immediate post-transplant period
149. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive no-hodgkin's lymphoma